secwatch.observer — SEC 8-K summary
======================================

Issuer:     OmniAb, Inc. (OABI)
CIK:        0001846253
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001193125-22-288305
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

OmniAb expects $25M milestone payment from Janssen after first US commercial sale of TECVAYLI
--------------------------------------------------------------------------------

- Janssen notified OmniAb that first US commercial sale of TECVAYLI (teclistamab) occurred, triggering $25M milestone.
- OmniAb expects to receive the $25M payment and recognize $25M milestone revenue in Q4 2022.
- Milestone arises from licensing agreement between OmniAb and an affiliate of Janssen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1846253/000119312522288305/0001193125-22-288305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1846253/000119312522288305/d390698d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-288305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer